Exelixis, Inc. Announces December 6 Webcast Of Its First Annual R&D Day
SOUTH SAN FRANCISCO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Exelixis, Inc. invites investors, the media and the general public to listen to a live webcast of its first annual R&D Day on December 6, 2005 at 9:30 a.m. (PST)/12:30 p.m. (EST).
(Photo: http://www.newscom.com/cgi-bin/prnh/20051114/SFM185 )
The webcast may be accessed in the Events Calendar page under Investors on the Exelixis website at http://www.exelixis.com .
An archive of this webcast will be available until 9:00 p.m. PST/12:00 a.m. EST on December 13, 2005. Access numbers for this replay are: 877-660-6853 (domestic) and 201-612-7415 (international); Conference ID number is: 177569.
About Exelixis
Exelixis, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics that will potentially enhance the care and lives of patients with cancer and other serious diseases. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a multinational Phase III clinical trial in bile duct tumor is ongoing and which has been exclusively licensed to Helsinn Healthcare S.A. with rights to reacquire commercial rights for North America; XL784, which is being advanced as a treatment for renal disease and is currently in a Phase I clinical trial using a newly developed capsule formulation of the compound; XL647, XL999, XL880, XL820, XL844 and XL184, anticancer compounds currently in Phase I clinical trials; and multiple compounds in preclinical development for diseases including cancer and various metabolic and cardiovascular disorders. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies including GlaxoSmithKline (GSK) and Bristol-Myers Squibb Company. Pursuant to a product development and commercialization agreement between Exelixis and GSK, GSK has the option, after completion of Phase IIa clinical trials by Exelixis, to elect to develop a certain number of compounds in Exelixis' product pipeline, which may include XL784 and the cancer compounds identified in this press release (other than XL119), thus potentially triggering milestone payments and royalties from GSK and co-promotion rights by Exelixis. For more information, please visit the company's web site at www.exelixis.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20051114/SFM185AP Archive: http://photoarchive.ap.orgAP PhotoExpress Network: PRN13PRN Photo Desk, photodesk@prnewswire.comExelixis, Inc.CONTACT: Charles Butler, Associate Director, Corporate Communications ofExelixis, Inc., +1-650-837-7277, or cbutler@exelixis.com
Web site: http://www.exelixis.com/